Abstract
Dual antiplatelet therapy (DAPT) remains the cornerstone therapy in the prevention of ischemic events following PCI. However, the mandatory duration of DAPT in new-generation drug-eluting stents (DES) remains a matter of debate. We aimed to evaluate efficacy and safety of short-term (≤6 months)
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
